Latest

1 story

Hide weekly roundups

Thursday, August 6

Cardurion registers Phase 2 CALIBRATE-HF trial of CaMKII inhibitor CRD-4730 in HFrEF

Trial updateCardurion Pharmaceuticals, Inc CRD-4730

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.